Session Information
-
WCLC 2021
2021 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
All times listed are in Mountain Time MDT (UTC-6:00)
PL - Plenary
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
WS - Workshops
IS - Industry Symposium
MTE - Meet the Expert
BEDG - Brain Exchange Discussion Groups
September 8 Wed
Sep 8 Thursday
September 9 Thu
Sep 9 Friday
September 10 Fri
Sep 10 Saturday
September 11 Sat
Sep 11 Sunday
September 12 Sun
Sep 12 Monday
September 13 Mon
Sep 13 Tuesday
September 14 Tue
Sep 14
-
+
P09 - Health Services Research/Health Economics - Lung Cancer Policy
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Health Services Research/Health Economics
-
+
P09.01 - Waiting Time and Lung Cancer Outcomes: Association and Methodological Results From a Systematic Review of Systematic and Scoping Reviews
00:00 - 00:00 | Presenter: Jianrong Zhang
- Abstract
Loading... -
+
P09.02 - A Clinical Evaluation Algorithm to Define Clinical Utility of Lung Nodule Diagnosis in a Multi-Collaborator Setting Using Real World Data
00:00 - 00:00 | Presenter: Stephen Deppen
- Abstract
Loading... -
+
P09.03 - Validation of a Real-World Mortality Endpoint for Advanced Non-Small Cell Lung Cancer Patients in China
00:00 - 00:00 | Presenter: Xian-ce Tang
- Abstract
Loading... -
+
P09.04 - Evaluating Mutational Differences Between Hispanics and Asians in NSCLC
00:00 - 00:00 | Presenter: Robert Chun-Hao Hsu
- Abstract
Loading... -
+
P09.05 - Variation of Treatment Recommendations for Stage III Non-Small-Cell Lung Cancer by Stage and Actionable Mutations
00:00 - 00:00 | Presenter: Dylann K Fujimoto
- Abstract
Loading... -
+
P09.06 - Patient Behaviors and Attitudes Towards Lung Cancer Medication Adherence
00:00 - 00:00 | Presenter: Christie Lagogianni
- Abstract
Loading... -
+
P09.07 - Integration of Smoking Cessation Services in Mobile Mammography and Mobile COVID Screening to Reach Rural Populations
00:00 - 00:00 | Presenter: Haylie Reed
- Abstract
Loading...
-
+
P10 - Health Services Research/Health Economics - What Happens In The Real-World?
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Health Services Research/Health Economics
-
+
P10.01 - Real World Data of Clinical Trial Eligibility and Outcome Analysis in Patients With Metastatic NSCLC
00:00 - 00:00 | Presenter: AMULYA YELLALA
- Abstract
Loading... -
+
P10.02 - Improved Survival of Elderly Patients with NSCLC Treated in the Immunotherapy Era: A Historical Cohort Study
00:00 - 00:00 | Presenter: Giacomo Pelizzari
- Abstract
Loading... -
+
P10.03 - Pembrolizumab With or Without Chemotherapy for Advanced Lung Cancer: A Real-World Analysis of Key Prognostic Factors
00:00 - 00:00 | Presenter: Shirish M. Gadgeel
- Abstract
Loading... -
+
P10.04 - Immunotherapy-Treated Non-Small Cell Lung Cancer Patients With Sensitizing Gene Alterations: A Real World Survival Analysis
00:00 - 00:00 | Presenter: Leia Khaddour
- Abstract
Loading... -
+
P10.05 - Adherence to Treatment Recommendations From Multidisciplinary Tumor Boards
00:00 - 00:00 | Presenter: Julia Roeper
- Abstract
Loading... -
+
P10.06 - Affiliation to the Labour Market in Denmark for Patients Under 60 Years of Age After Diagnosis and Treatment for ALK-Positive NSCLC
00:00 - 00:00 | Presenter: Jon Lykkegaard Andersen
- Abstract
Loading... -
+
P10.07 - Real-World US Treatment Patterns and Clinical Outcomes in Advanced NSCLC After Prior Platinum Chemotherapy and Immunotherapy
00:00 - 00:00 | Presenter: Timothy W. Smith
- Abstract
Loading... -
+
P10.08 - Comparing Lung Cancer in Never Smokers and Ever Smokers in Asian or Asian American Patients Treated at a Tertiary Urban Public Hospital in New York
00:00 - 00:00 | Presenter: Gianna Kroening
- Abstract
Loading... -
+
P10.09 - Efficacy and Toxicity of EGFR-TKI in Frail NSCLC with EGFR Mutation: A Retrospective Analysis in a Single Institution
00:00 - 00:00 | Presenter: yuki akazawa
- Abstract
Loading... -
+
P10.10 - Trends in Treatment Patterns and Survival in Advanced NSCLC Patients Treated at Frankfurt University Hospital in 2012–2018
00:00 - 00:00 | Presenter: Andrea Wolf
- Abstract
Loading... -
+
P10.11 - Real-World Experience With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer at Frankfurt University Hospital
00:00 - 00:00 | Presenter: Andrea Wolf
- Abstract
Loading... -
+
P10.12 - A Thorough Look at the Clinical Characteristics and Disease Burden of Lung Cancer Patients in Chinese County Area
00:00 - 00:00 | Presenter: Jun Wan
- Abstract
Loading... -
+
P10.13 - Real World Outcomes for Non Small Cell Lung Cancer Treated With Checkpoint Inhibitors in Lebanon, A Multicenter Observational Study
00:00 - 00:00 | Presenter: Fadi Louis Nasr
- Abstract
Loading... -
+
P10.14 - ctDNA and Real-World Response (rwR) in Patients With Lung Cancer From A Prospective Real-World Clinico-Genomic (PCG) Study
00:00 - 00:00 | Presenter: Ari VanderWalde
- Abstract
Loading...
-
+
P11 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Clinical Trials in Progress
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
-
+
P11.01 - Phase I Trial of in Situ Vaccination With Autologous CCL21-Modified Dendritic Cells (CCL21-DC) Combined With Pembrolizumab for Advanced NSCLC
00:00 - 00:00 | Presenter: Edward B Garon
- Abstract
Loading... -
+
P11.02 - Targeting the Tumor Neovasculature in Lung Cancer: A Phase I Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: George Blumenschein, Jr
- Abstract
Loading... -
+
P11.03 - SHR-1316 in Combination With Fluzoparib in Relapsed Small-Cell Lung Cancer: An Open-Label, Multicenter, Two-Stage, Phase Ⅰb Trial
00:00 - 00:00 | Presenter: Yun Fan
- Abstract
Loading...
-
+
P12 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Clinical Efficacy of ICI, Predicitve Biomarkers and RT Plus ICI
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
-
+
P12.01 - A Novel 89Zr-α-PD-1 Immuno-PET-CT May Improve Pseudoprogression Detection in a Lung Cancer Murine Model Receiving Immunotherapy
00:00 - 00:00 | Presenter: Ignacio Gil-Bazo
- Abstract
Loading... -
+
P12.02 - Systemic Anticancer Therapy Upregulate Plasma Levels of Damage-Associated Molecular Patterns in Patients With Advanced Lung Cancer
00:00 - 00:00 | Presenter: Hiroyuki Inoue
- Abstract
Loading... -
+
P12.03 - The Time of Anti-PD-1 Infusion Improves Survival Outcomes by Fasting Conditions Simulation in Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Anna Vilalta-Lacarra
- Abstract
Loading... -
+
P12.04 - Radiation Mediates IDO1 Dynamic Changes in KRAS Mutation Lung Cancer Cell Lines
00:00 - 00:00 | Presenter: Yanli Lan
- Abstract
Loading... -
+
P12.05 - Neutrophil Elastase as Combined Immunotherapy Target for Treating NSCLC
00:00 - 00:00 | Presenter: Hong Cheng
- Abstract
Loading... -
+
P12.06 - Computational Omics Biology Model (CBM) Identifies PD-L1 Immunotherapy Response Criteria Based on Genomic Signature of NSCLC
00:00 - 00:00 | Presenter: Michael Castro
- Abstract
Loading... -
+
P12.07 - Radiation Mediated Down-Regulation of Indoleamine 2,3-dioxygenase 1 (IDO1) Expression in Lung Cancer Cells is Associated with iNOS-NO Pathway
00:00 - 00:00 | Presenter: Wenhu Pi
- Abstract
Loading...
-
+
P13 - Immunotherapy (Phase II/III Trials) - Clinical Efficacy of ICI, Predictive Biomarkers and RT Plus ICI
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P13.01 - Use of Antibiotics Is Associated With an Increase in Immunotherapy Related Adverse Effects in Patients With Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: umair majeed
- Abstract
Loading...
-
+
P14 - Immunotherapy (Phase II/III Trials) - Clinical Trial in Progress
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P14.01 - Phase 3 Study of First-Line Pembrolizumab ± Vibostolimab (anti-TIGIT) in Patients With PD-L1‒Positive Metastatic NSCLC
00:00 - 00:00 | Presenter: Matthew D. Hellmann
- Abstract
Loading... -
+
P14.02 - Phase III Trial of Pembrolizumab‑Chemotherapy Versus Pembrolizumab in First‑Line of Advanced NSCLC with PD‑L1 ≥50%: PERSEE
00:00 - 00:00 | Presenter: Renaud Descourt
- Abstract
Loading... -
+
P14.03 - Vibostolimab Plus Pembrolizumab With/Without Docetaxel vs Docetaxel in NSCLC After Platinum Chemotherapy and Immunotherapy
00:00 - 00:00 | Presenter: Solange Peters
- Abstract
Loading... -
+
P14.04 - A Phase 2 Multicenter Study of Iovance Autologous Tumor Infiltrating Lymphocytes (TIL, LN-145) Cell Therapy in Patients With Metastatic NSCLC
00:00 - 00:00 | Presenter: Erminia Massarelli
- Abstract
Loading... -
+
P14.05 - Phase 2, Study of Iovance Autologous Tumor Infiltrating Lymphocytes (Lifileucel, LN-144, LN-145, LN-145-S1) In Patients With Solid Tumors
00:00 - 00:00 | Presenter: Scott Gettinger
- Abstract
Loading... -
+
P14.06 - Toripalimab in Combination With Bevacizumab and Platinum-Based Chemotherapy in Patients with Untreated Advanced PSC: A Phase II Study
00:00 - 00:00 | Presenter: Juan Li
- Abstract
Loading... -
+
P14.07 - PERLA: Randomized Phase II Trial of Dostarlimab + Chemotherapy (CT) vs Pembrolizumab + CT in Metastatic Non-Squamous NSCLC
00:00 - 00:00 | Presenter: Alexander Spira
- Abstract
Loading...
-
+
P15 - Immunotherapy (Phase II/III Trials) - Early Stage NSCLC
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P15.01 - Phase II Prospective Study of Adjuvant Pembrolizumab in N2 Positive NSCLC Treated With Neoadjuvant CCRT Followed by Surgery
00:00 - 00:00 | Presenter: Sehhoon Park
- Abstract
Loading... -
+
P15.02 - Toripalimab and Platinum-Doublet Chemotherapy as Neoadjuvant Therapy for Potentially Resectable Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Yongchang Zhang
- Abstract
Loading...
-
+
P16 - Immunotherapy (Phase II/III Trials) - First-Line, Advanced NSCLC
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P16.01 - Clonal Landscape Predicts Outcome in Lung Squamous Cell Carcinoma Patients with a Low Tumor Mutational Burden
00:00 - 00:00 | Presenter: Stas Fridland
- Abstract
Loading... -
+
P16.02 - Atezolizumab, Bevacizumab and Chemotherapy (IMpower150) in Stage IV Non-Small Cell Lung Cancer: The Australian Experience
00:00 - 00:00 | Presenter: Samantha Larna Dean
- Abstract
Loading... -
+
P16.03 - SWItch Maintenance PEmbrolizumab in patients with Non Small Cell Lung Cancer (SWIPE): Final Analysis
00:00 - 00:00 | Presenter: Haris Charalambous
- Abstract
Loading... -
+
P16.04 - A Phase II Clinical Study Evaluating Camrelizumab Combined With Apatinib and Albumin Paclitaxel for Advanced Non-Small CellLung Cancer
00:00 - 00:00 | Presenter: Lin Wu
- Abstract
Loading... -
+
P16.05 - Real World Data of First-Line Treatment With Pembrolizumab for Highly PD-L1-Expressing NSCLC
00:00 - 00:00 | Presenter: maki kobayashi
- Abstract
Loading... -
+
P16.06 - Comparison of Clinical Outcomes of Patients With Advanced NSCLC In Clinical Trials and in the Real World Received PD-1/PD-L1 Inhibitor
00:00 - 00:00 | Presenter: Huijuan wang
- Abstract
Loading... -
+
P16.07 - ARC-10: Phase 3 Study of Zimberelimab ± Domvanalimab vs Standard Chemotherapy in Front-Line, PD-L1-High, Metastatic NSCLC
00:00 - 00:00 | Presenter: Yu-Chung Li
- Abstract
Loading...
-
+
P17 - Immunotherapy (Phase II/III Trials) - First-Line, Advanced, Squamous NSCLC
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P17.01 - KEYNOTE-407 China Extension Final Analysis: Pembrolizumab Plus Chemotherapy for the Treatment of Metastatic Squamous NSCLC
00:00 - 00:00 | Presenter: Ying Cheng
- Abstract
Loading... -
+
P17.02 - RATIONALE 307: A Subgroup Analysis of Tislelizumab Plus Chemo vs Chemo Alone As 1L Treatment for Stage IIIB Advanced Sq NSCLC
00:00 - 00:00 | Presenter: Shun Lu
- Abstract
Loading... -
+
P17.03 - Sintilimab With Two Cycles Nab-Paclitaxel / Platinum as First Line Therapy for Advanced Squamous Non–Small-Cell Lung Cancer
00:00 - 00:00 | Presenter: Huijuan wang
- Abstract
Loading...
-
+
P18 - Immunotherapy (Phase II/III Trials) - IO and Targeted Therapy
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P18.01 - Treatment Efficacy of HER2-Mutant Lung Adenocarcinoma by Immune Checkpoint Inhibitors
00:00 - 00:00 | Presenter: Chunxia Su
- Abstract
Loading...
first
prev
